A method of determining a probability that a human test subject has colorectal cancer as opposed to not having colorectal cancer is disclosed. The method comprises, for each gene of a set of one or more genes selected from the group consisting of ANXA3, CLEC4D, IL2RB, LMNB1, PRRG4, TNFAIP6 and VNN1: determining a level of RNA encoded by the gene in blood of the test subject, thereby generating test data; providing positive control data representing levels of RNA encoded by the gene in blood of human control subjects having colorectal cancer, and providing negative control data representing levels of RNA encoded by the gene in blood of human control subjects not having colorectal cancer; and determining a probability that the test data corresponds to the positive control data and not to the negative control data, where the probability that the test data corresponds to the positive control data and not to the negative control data represents the probability that the test subject has colorectal cancer as opposed to not having colorectal cancer.
-------------------------------------------------
The equivalent European patent EP2281059B1 has been extended until April 10, 2029
---------------------------------------
Can't find much out about worldwide patent W02010012086A1. Methods and compostions for determining severity of heart failure in a subject. Unless its part of the patent below:
---------------------------------------------------------
Worldwide patent W02004112589A2. .
The method of claim 1, wherein the disease is selected from the group consisting of: liver cancer, bladder cancer, brain cancer, prostate cancer, ovarian cancer, kidney cancer, gastric cancer, lung cancer, breast cancer, nasopharyngeal cancer, pancreatic cancer, osteoarthritis, depression, hypertension, heart failure, obesity, rheumatoid arthritis, hyperlipidemia, lung disease, chagas disease, allergies, schizophrenia, asthma, manic depression syndrome, ankylosing spondylitis, guillain bane syndrome, fibromyalgia, multiple sclerosis, muscular dystrophy, septic joint arthroplasty, hepatitis, crohn's disease or colitis, or malignant hyperthermia susceptibility, psoriasis, thyroid disorder, irritable bowel syndrome, osteoporosis, migraines, eczema, or a heart murrner.
The method of claim 3, wherein said disease of interest is selected from the group consisting of: liver cancer, bladder cancer, brain cancer, prostate cancer, ovarian cancer, kidney cancer, gastric cancer, lung cancer, breast cancer, nasopharyngeal cancer, pancreatic cancer, osteoarthritis, depression, hypertension, heart failure, obesity, rheumatoid arthritis, hyperlipidemia, lung disease, chagas disease, allergies, schizophrenia and asthma, manic depression syndrome, ankylosing spondylitis, guillain bane syndrome, fibromyalgia, multiple sclerosis, muscular dystrophy, septic joint arthroplasty, hepatitis, crohn's disease or colitis, malignant hyperthermia susceptibility, psoriasis, thyroid disorder, irritable bowel syndrome, osteoporosis, migraines, eczema, or a heart murmer, alzheimer's, CAD, Diabetes, or colorectal cancer.
The method of claim 8, wherein said first and second disease or condition of interest of said pair of disease and/or conditions, are selected from the group consisting of rheumatoid arthritis, osteoarthritis, schizophrenia, manic depression syndrome, liver cancer, hepatitis, bladder cancer, kidney cancer, bladder cancer, testicular cancer, pancreatic cancer, kidney cancer, liver cancer, stomach cancer, colon cancer, Chagas disease, heart failure, coronary artery disease, asymptomatic Chagas Disease, symptomatic Chagas Disease, alzheimer's Disease, allergies, systemic steroids, allergy, Type II Diabetes, obesity, hypertension, , hyperliidemia, lung disease, bladder cancer, asthma, psoriasis, thyroid disorder, irritable bowel syndrome, osteoporosis, migraine headaches, excema, NASH, Crohn's colitis, chronic cholecystitis, cervical cancer, cardiovascular disease, and neurological disease.